Market Overview
According to Market Genics, the AI in Pharmacovigilance Market is estimated to be valued at USD 0.4 Billion in 2025 and is projected to reach USD 1.9 Billion by 2035, registering a CAGR of 17.1% during the forecast period.
The market is experiencing rapid growth due to the increasing demand for automated drug safety monitoring, rising volumes of adverse event reports, and g rowing adoption of artificial intelligence across the pharmaceutical industry. AI-powered pharmacovigilance solutions leverage machine learning (ML), natural language processing (NLP), robotic process automation (RPA), predictive analytics, and cloud computing to streamline adverse event detection, case processing, signal management, and regulatory reporting.
The increasing complexity of global drug development, stringent regulatory requirements, expanding real-world evidence (RWE) initiatives, and the growing use of electronic health records (EHRs) are accelerating the adoption of AI-based pharmacovigilance platforms. These technologies enable pharmaceutical companies and healthcare organizations to improve patient safety, enhance compliance, reduce operational costs, and accelerate decision-making.
To obtain a free sample research report - https://marketgenics.co/download-report-sample/ai-in-pharmacovigilance-market-59587?utm_source=Free&utm_medium=ruchika
Market Growth Drivers
Increasing Volume of Adverse Drug Event Reports
The growing number of adverse drug reaction (ADR) reports generated from healthcare providers, patients, clinical trials, and post-marketing surveillance is driving the need for AI-powered pharmacovigilance solutions.
Rising Adoption of Artificial Intelligence in Drug Safety
AI technologies automate case intake, medical coding, literature screening, duplicate detection, and signal identification, significantly improving operational efficiency and reducing manual workloads.
Stringent Regulatory Compliance Requirements
Global regulatory agencies continue to strengthen pharmacovigilance guidelines, encouraging pharmaceutical companies to adopt AI-enabled systems for accurate safety reporting and compliance.
Growth in Real-World Evidence and Real-World Data
The increasing use of electronic health records, insurance claims, wearable devices, and patient registries is creating vast datasets that AI can analyze to identify emerging safety signals.
Expansion of Biopharmaceutical Research
Growing investments in biologics, biosimilars, gene therapies, vaccines, and personalized medicine are increasing the complexity of drug safety monitoring throughout the product lifecycle.
Cloud-Based Pharmacovigilance Platforms
Cloud deployment enables scalable data processing, secure collaboration, and real-time monitoring across global pharmacovigilance operations.
Key Players
- Oracle Health
- IQVIA
- ArisGlobal
- Veeva Systems
- Cognizant
- Accenture
- IBM Corporation
- Microsoft Corporation
- SAS Institute
- Parexel
- ICON plc
- Labcorp Drug Development
- TCS (Tata Consultancy Services)
- Capgemini
- Wipro Limited
Regional Insights
North America
North America dominates the AI in Pharmacovigilance Market due to its advanced pharmaceutical industry, robust regulatory environment, high adoption of AI technologies, and significant investments in drug safety and clinical research.
Europe
Europe continues to hold a substantial market share driven by increasing pharmacovigilance regulations, expanding pharmaceutical research, and widespread adoption of digital healthcare technologies.
Asia-Pacific
Asia-Pacific is expected to register the fastest CAGR during the forecast period due to growing pharmaceutical manufacturing, increasing clinical research outsourcing, expanding healthcare digitalization, and rising AI adoption.
Latin America
Growing pharmaceutical production, improving healthcare infrastructure, and increasing regulatory focus on drug safety are supporting market expansion across Brazil and Mexico.
Middle East & Africa
The region is gradually adopting AI-powered pharmacovigilance solutions as governments strengthen healthcare systems, pharmaceutical regulations, and digital health initiatives.
Future Outlook
The AI in Pharmacovigilance Market is expected to witness significant innovation as pharmaceutical companies increasingly adopt intelligent automation for drug safety management.
Key trends shaping the future include:
- AI-powered adverse event detection and case processing
- Natural language processing for literature and social media monitoring
- Predictive safety signal detection using machine learning
- Integration of real-world evidence (RWE) and real-world data (RWD)
- Cloud-based pharmacovigilance platforms
- Robotic Process Automation (RPA) for regulatory workflows
- AI-assisted benefit-risk assessment
- Automated regulatory submissions and compliance reporting
- Generative AI for pharmacovigilance documentation
- End-to-end digital drug safety ecosystems
As pharmaceutical companies continue to prioritize patient safety, regulatory compliance, and operational efficiency, AI-driven pharmacovigilance platforms will become increasingly essential throughout the drug development lifecycle. Continuous advancements in AI, automation, and cloud computing are expected to reduce case processing times, improve signal detection accuracy, and enhance global pharmacovigilance operations.
Related Reports:
